Lenalidomide Observational Study in Patients With Mantle Lymphoma in Relapse/Refraction. Spanish Programme RRMCL Results.

Overview

This is a multicentric, observational and retrospective study of the use of lenalidomide in patients with relapsed or refractory mantle cell lymphoma that are included in the RRMCL spanish program. The lenalidomide effectiveness and tolerability data will be retrospectely collected until the 30 of April 2018.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: June 15, 2020

Interventions

  • Drug: Lenalidomide
    • Lenalidomide effectiveness and tolerability data analysis, that will be retrospectively collected until the 30 of April 2018.

Arms, Groups and Cohorts

  • Mantle cell lymphoma treated with lenalidomide cohort
    • Patients diagnosed with mantle cell lymphoma treated with leanalidomide through the RRMCL spanish program.

Clinical Trial Outcome Measures

Primary Measures

  • Experience of real clinal practice lenalidomide use.
    • Time Frame: Start of observation period (first medical record available on site) up to last medical record available on site or the end of the observation period (31 December 2019), whichever occurred first
    • Results of the the usage in real clinical practice of the lenalidomide monotherapy or combination treatment in patients with relapsed or refractory mantle cell lymphoma that aren´t candidate to other alternative treatments inside the RRMCL spanish program.

Secondary Measures

  • Proportion of patients that achieve objective response.
    • Time Frame: Start of observation period (first medical record available on site) up to last medical record available on site or the end of the observation period (31 December 2019), whichever occurred first
    • The objective response will be measured in terms of complete response, not confirmed complete response and partial response according to the 2007 International Working Group criteria after the 6º treatment cycle.
  • Duration of the response.
    • Time Frame: Start of observation period (first medical record available on site) up to last medical record available on site or the end of the observation period (31 December 2019), whichever occurred first
    • Partial and complete response duration.
  • Verify the disease free survival.
    • Time Frame: Start of observation period (first medical record available on site) up to last medical record available on site or the end of the observation period (31 December 2019), whichever occurred first
    • The disease free survival is defined as the time that passes from the inclusion in the record until a control is done or takes place a relapse (local or distant).
  • Verify the disease overall survival.
    • Time Frame: Start of observation period (first medical record available on site) up to last medical record available on site or the end of the observation period (31 December 2019), whichever occurred first
    • The disease overall survival is defined as the time that passes from the inclusion in the record until a control is done or the patient´s death.
  • Evaluate the incidence of treatment adverse events.
    • Time Frame: Start of observation period (first medical record available on site) up to last medical record available on site or the end of the observation period (31 December 2019), whichever occurred first
    • Number and description of adverse effects due to the lenalidomide treatment.

Participating in This Clinical Trial

Inclusion Criteria

  • ≥ 18 years old. – Diagnosed with relapsed or refractory mantle cell lymphoma verified by a tissue biopsy. – Treated with monotherapy or combination of lenalidomide. – Not candidate for any of the therapeutic options approved until that date for this disease. – Not candidate or unable to be included in any clinical trial due to availability or geographical difficulty. – Registered in the RRMCL spanish program. Exclusion Criteria:

  • ECOG > 2. – Patients with uncontrolled comorbidities. – Blastoid variant. – Central nervous system tumor infiltration. – HIV, HBV and/or HCV active infection. – Radiotherapy concomitant treatment or that have received radiotherapy in the previous 30 days to the beginning of the first cycle of lenalidomide. – Diagnosed with other active solid tumor except for basal cell carcinoma skin cancer. – Patients that haven´t completed at least one complete cycle of the treatment.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Investigator Details

  • Lead Sponsor
    • Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Carlos García Pérez, Study Chair, Hospital Universitario Virgen Macarena
  • Overall Contact(s)
    • Carlos García Pérez, 955 00 80 00, administracion.eecc.hvm.sspa@juntadeandalucia.es

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.